Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study

Journal of Medical Virology

Volumn 91, Issue 4, 2019, Pages 588-597

  Leneva, Irina A ^a   Falynskova, Irina N ^a   Makhmudova, Nailya R ^a   Poromov, Artem A ^a,b   Yatsyshina, Svetlana B ^c   Maleev, Viktor V ^c  

^a MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

Author keywords

chemotherapy; drug specificity; influenza virus; resistance

Indexed keywords

ARBIDOL; OSELTAMIVIR; UMIFENOVIR; ANTIVIRUS AGENT; INDOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA VIRUS; MALE; MDCK CELL LINE; NONHUMAN; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS INHIBITION; VIRUS ISOLATION; ADOLESCENT; AGED; ANIMAL; CLINICAL TRIAL (TOPIC); DOG; DRUG EFFECT; INFLUENZA; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; ORTHOMYXOVIRIDAE; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; VIROLOGY; VIRUS REPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DOGS; FEMALE; HUMANS; INDOLES; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ORTHOMYXOVIRIDAE; RUSSIA; VIRUS REPLICATION; YOUNG ADULT;

EID: 85058027597     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.25358     Document Type: Article

References (39)

1. Hayden FG. Antiviral resistance in influenza viruses--implications for management and pandemic response. N Engl J Med. 2006;354(8):785-788. https://doi.org/10.1056/NEJMp068030
2. Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22-29. https://doi.org/10.1016/j.coviro.2014.04.009
3. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363(6428):418-423. https://doi.org/10.1038/363418a0
4. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119(4):681-690.
5. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282(13):1240-1246.
6. Nicholson K, Aoki F, Osterhaus A, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (London, England). 2000;355(9218):1845-1850.
7. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (London, England). 2004;364(9436):759-765. https://doi.org/10.1016/S0140-6736(04)16934-1
8. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48(4):389-396. https://doi.org/10.1086/596311
9. Li T, Chan M, Lee N. Clinical Implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929-4944. Hagedorn C, ed. https://doi.org/10.3390/v7092850 doi
10. Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015;117:27-38. https://doi.org/10.1016/j.antiviral.2015.02.003
11. Takashita E, Kiso M, Fujisaki S, et al. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan. Antimicrob Agents Chemother. 2015;59(5):2607-2617. https://doi.org/10.1128/AAC.04836-14
12. Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill Bull Eur sur les Mal Transm=Eur Commun Dis Bull. 2014;19(1):20666.
13. Huang W, Li X, Cheng Y, et al. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013–2014 influenza season in Mainland China. Virol J. 2015;12:96. https://doi.org/10.1186/s12985-015-0317-1
14. Okomo-Adhiambo M, Fry AM, Su S, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14. Emerg Infect Dis. 2015;21(1):136-141. https://doi.org/10.3201/eid2101.141006
15. Toyama Chemical Co. L. The new drug application approval of “AVIGAN® Tablet 200mg” in Japan for the anti-influenza virus drug. 2014.
16. Shionogi & Co. Ltd. XOFLUZA (Baloxavir Marboxil) tablets 10mg/20 mg approved for the treatment of influenza types A and B In Japan. 2018:1.
17. Takashita E, Ejima M, Ogawa R, et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 2016;132:170-177. https://doi.org/10.1016/j.antiviral.2016.06.007
18. Daikoku T, Yoshida Y, Okuda T, Shiraki K. Characterization of susceptibility variants of influenza virus grown in the presence of T-705. J Pharmacol Sci. 2014;126(3):281-284. https://doi.org/10.1254/jphs.14156SC
19. Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. https://doi.org/10.1038/s41598-018-27890-4
20. Jones JC, Kumar G, Barman S, et al. Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors. mBio. 2018;9(2):00430-18. https://doi.org/10.1128/mBio.00430-18
21. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132-140. https://doi.org/10.1016/j.antiviral.2008.10.009
22. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-214. https://doi.org/10.1073/pnas.1617020114
23. Leneva IA, Burtseva EI, Yatsyshina SB, et al. Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010–2011 influenza season in Russia. Int J Infect Dis. 2016;43:77-84. https://doi.org/10.1016/j.ijid.2016.01.001
24. Burtseva EI, Shevchenko ES, Leneva IA, et al. Rimantadine and arbidol sensitivity of influenza viruses that caused epidemic morbidity rise in Russia in the 2004-2005 season. Vopr Virusol. 2007;52(2):24-29.
25. Fediakina IT, Shchelkanov M, Deriabin PG, et al. Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture. Antibiot i khimioterapiia=Antibiot chemoterapy [sic]. 2011;56(3-4):3-9.
26. Boriskin Y, Leneva I, Pecheur E-I, Polyak S. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997-1005.
27. Wang MZ, Cai BQ, Li LY, et al. Efficacy and safety of arbidol in treatment of naturally acquired influenza. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004;26(3):289-293.
28. Bulgakova VA, Poromov AA, Grekova AI, et al. Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups. Ter Arkh. 2017;89(1):62. https://doi.org/10.17116/terarkh201789162-71
29. Kiselev OI, Maleev VV, Deeva EG, et al. Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR. Ter Arkh. 2015;87(1):88-96.
30. Webster RG, Cox N, Stöhr K. World Health Organization. WHO Manual on Animal Influenza Diagnosis and Surveillance. 2002:97p. Available at. http://www.who.int/csr/resources/publications/influenza/en/whocdscsrncs20025rev.pdf
31. Grambas S, Hay AJ. Maturation of influenza A virus hemagglutinin--estimates of the pH encountered during transport and its regulation by the M2 protein. Virology. 1992;190(1):11-18.
32. Hurt A. Standard operating procedure WHO-025: fluorometric neuraminidase inhibition assay. Official copy. World Heal Organ Collab Cent Ref Res Influ Aust. 2007:10p. Available at. http://www.nisn.org/documents/A.Hurt_Protocol_for_NA_fluorescence.pdf
33. Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS One. 2016;10(12):1-13. https://doi.org/10.1371/journal.pone.0146021
34. Review of the 2012–2013 winter influenza season, northern hemisphere. Weekly epidemiological record. World Heal Organ. 2013;22(88):225–232.
35. Review of the 2013–2014 winter influenza season, northern hemisphere. Weekly epidemiological record. World Heal Organ. 2014;(23):245-256.
36. Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84-94. https://doi.org/10.1016/j.antiviral.2014.04.006
37. Leneva IA, Fadeeva NI, Fedyakina IT, et al. Study of arbidol, a new anti-influenzal drug, using immuno-enzymated detection of virus specific antigens. Chem Pharm J. 1994;9:4-15.
38. Ujike M, Ejima M, Anraku A, et al. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009–2010. Emerg Infect Dis. 2011;17(3):470-479. 2011;17:470-479. https://doi.org/10.3201/eid1703.101188
39. Gubareva LV, Kaiser L, Matrosovich MN, Soo-hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis. 2001;183(4):523-531. https://doi.org/10.1086/318537